

Johan A Maertens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9219888/publications.pdf>

Version: 2024-02-01

156
papers

19,930
citations

38660

50
h-index

11030

137
g-index

161
all docs

161
docs citations

161
times ranked

13938
citing authors

#	ARTICLE	IF	CITATIONS
1	Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. <i>Clinical Infectious Diseases</i> , 2008, 46, 1813-1821.	2.9	4,375
2	Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia. <i>New England Journal of Medicine</i> , 2007, 356, 348-359.	13.9	1,613
3	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020, 71, 1367-1376.	2.9	1,429
4	Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenia. <i>New England Journal of Medicine</i> , 2004, 351, 1391-1402.	13.9	868
5	Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by <i>Aspergillus</i> and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. <i>Lancet</i> , The, 2016, 387, 760-769.	6.3	695
6	Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial). <i>Clinical Infectious Diseases</i> , 2007, 44, 1289-1297.	2.9	663
7	Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. <i>Lancet Oncology</i> , The, 2009, 10, 855-864.	5.1	620
8	Galactomannan and Computed Tomography-Based Preemptive Antifungal Therapy in Neutropenic Patients at High Risk for Invasive Fungal Infection: A Prospective Feasibility Study. <i>Clinical Infectious Diseases</i> , 2005, 41, 1242-1250.	2.9	558
9	Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 828-837.	4.6	528
10	Galactomannan in Bronchoalveolar Lavage Fluid. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 27-34.	2.5	457
11	High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3889-3897.	0.8	392
12	Combination Antifungal Therapy for Invasive Aspergillosis. <i>Annals of Internal Medicine</i> , 2015, 162, 81-89.	2.0	376
13	Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. <i>Clinical Infectious Diseases</i> , 2008, 47, 674-683.	2.9	368
14	Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. <i>Blood</i> , 2011, 117, 6375-6382.	0.6	281
15	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. <i>Intensive Care Medicine</i> , 2020, 46, 1524-1535.	3.9	278
16	Genetic PTX3 Deficiency and Aspergillosis in Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2014, 370, 421-432.	13.9	265
17	International expert opinion on the management of infection caused by azole-resistant <i>Aspergillus fumigatus</i> . <i>Drug Resistance Updates</i> , 2015, 21-22, 30-40.	6.5	262
18	ECIL guidelines for the diagnosis of <i>Pneumocystis jirovecii</i> pneumonia in patients with haematological malignancies and stem cell transplant recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2386-2396.	1.3	226

#	ARTICLE	IF	CITATIONS
19	Early Detection of Toxoplasma Infection by Molecular Monitoring of Toxoplasma gondii in Peripheral Blood Samples after Allogeneic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2005, 40, 67-78.	2.9	221
20	ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2397-2404.	1.3	211
21	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). <i>Journal of Hematology and Oncology</i> , 2021, 14, 168.	6.9	189
22	European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3221-3230.	1.3	186
23	Optimization of the Cutoff Value for the Aspergillus Double-Sandwich Enzyme Immunoassay. <i>Clinical Infectious Diseases</i> , 2007, 44, 1329-1336.	2.9	163
24	Detection of Galactomannan in Bronchoalveolar Lavage Fluid Samples of Patients at Risk for Invasive Pulmonary Aspergillosis: Analytical and Clinical Validity. <i>Journal of Clinical Microbiology</i> , 2012, 50, 1258-1263.	1.8	159
25	Antifungal drugs: What brings the future?. <i>Medical Mycology</i> , 2019, 57, S328-S343.	0.3	141
26	A Randomized, Double-Blind, Multicenter Study of Caspofungin Versus Liposomal Amphotericin B for Empiric Antifungal Therapy in Pediatric Patients With Persistent Fever and Neutropenia. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, 415-420.	1.1	135
27	Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients—a multinational observational study by the European Confederation of Medical Mycology. <i>Clinical Microbiology and Infection</i> , 2022, 28, 580-587.	2.8	133
28	Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. <i>Blood</i> , 2010, 115, 2586-2591.	0.6	131
29	Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). <i>Leukemia</i> , 2019, 33, 844-862.	3.3	131
30	Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Blood</i> , 2022, 139, 2347-2354.	0.6	131
31	CD34+CD38 ^{low} leukemic stem cell frequency to predict outcome in acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 1102-1112.	3.3	130
32	Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. <i>Lancet, The</i> , 2021, 397, 499-509.	6.3	119
33	Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. <i>Cancer</i> , 2009, 115, 355-362.	2.0	110
34	Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation. <i>New England Journal of Medicine</i> , 2019, 381, 1136-1147.	13.9	108
35	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. <i>Intensive Care Medicine</i> , 2021, 47, 819-834.	3.9	106
36	Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse. <i>JAMA Oncology</i> , 2018, 4, 1245.	3.4	97

#	ARTICLE	IF	CITATIONS
37	Nationwide Surveillance of Azole Resistance in Aspergillus Diseases. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4569-4576.	1.4	81
38	Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. <i>Microbial Cell</i> , 2018, 5, 300-326.	1.4	81
39	Phase 1B Study of the Pharmacokinetics and Safety of Posaconazole Intravenous Solution in Patients at Risk for Invasive Fungal Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3610-3617.	1.4	79
40	Application of the 2008 Definitions for Invasive Fungal Diseases to the Trial Comparing Voriconazole Versus Amphotericin B for Therapy of Invasive Aspergillosis: A Collaborative Study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group. <i>Clinical Infectious Diseases</i> , 2015, 60, 713-720.	2.9	75
41	Early Serum Galactomannan Trend as a Predictor of Outcome of Invasive Aspergillosis. <i>Journal of Clinical Microbiology</i> , 2012, 50, 2330-2336.	1.8	74
42	Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. <i>Leukemia</i> , 2021, 35, 3585-3588.	3.3	72
43	Phagosomal removal of fungal melanin reprograms macrophage metabolism to promote antifungal immunity. <i>Nature Communications</i> , 2020, 11, 2282.	5.8	68
44	Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2359-2367.	1.3	65
45	Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). <i>Leukemia</i> , 2022, 36, 1467-1480.	3.3	63
46	The role of antifungal treatment in hematology. <i>Haematologica</i> , 2012, 97, 325-327.	1.7	60
47	Role of Non-Culture-Based Tests, with an Emphasis on Galactomannan Testing for the Diagnosis of Invasive Aspergillosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015, 36, 650-661.	0.8	60
48	Galactomannan, a Surrogate Marker for Outcome in Invasive Aspergillosis: Finally Coming of Age. <i>Frontiers in Microbiology</i> , 2018, 9, 661.	1.5	60
49	Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3406-3413.	1.3	58
50	Single and Multiple Dose MultiStem (Multipotent Adult Progenitor Cell) Therapy Prophylaxis of Acute Graft-versus-Host Disease in Myeloablative Allogeneic Hematopoietic Cell Transplantation: A Phase 1 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 720-728.	2.0	56
51	Evaluation of Bronchoalveolar Lavage Fluid Cytokines as Biomarkers for Invasive Pulmonary Aspergillosis in At-Risk Patients. <i>Frontiers in Microbiology</i> , 2017, 8, 2362.	1.5	54
52	Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the <sc>FUN</sc>gal infections Definitions in <sc>ICU</sc> patients (<sc>FUNDICU</sc>) project. <i>Mycoses</i> , 2019, 62, 310-319.	1.8	53
53	Impact of Hypoalbuminemia on Voriconazole Pharmacokinetics in Critically Ill Adult Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6782-6789.	1.4	52
54	Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	52

#	ARTICLE	IF	CITATIONS
55	Prevalence of voriconazole-resistant invasive aspergillosis and its impact on mortality in haematology patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2759-2766.	1.3	52
56	Lateral flow assays for diagnosing invasive pulmonary aspergillosis in adult hematology patients: A comparative multicenter study. <i>Medical Mycology</i> , 2020, 58, 444-452.	0.3	50
57	Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease. <i>Mycoses</i> , 2011, 54, e449-55.	1.8	49
58	Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial. <i>Intensive Care Medicine</i> , 2021, 47, 674-686.	3.9	49
59	Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system. <i>Medical Mycology</i> , 2020, 58, 417-424.	0.3	48
60	Increasing candidaemia incidence from 2004 to 2015 with a shift in epidemiology in patients preexposed to antifungals. <i>Mycoses</i> , 2018, 61, 127-133.	1.8	47
61	Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 720-727.	2.0	47
62	Post-Transplantation Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplantation: Results of the Prospective Randomized HOVON-96 Trial in Recipients of Matched Related and Unrelated Donors. <i>Blood</i> , 2019, 134, 1-1.	0.6	47
63	COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP. <i>Blood Advances</i> , 2022, 6, 2427-2433.	2.5	46
64	Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Journal of Hematology and Oncology</i> , 2017, 10, 20.	6.9	43
65	Diagnosis and treatment of COVID-19 associated pulmonary aspergillosis in critically ill patients: results from a European confederation of medical mycology registry. <i>Intensive Care Medicine</i> , 2021, 47, 1158-1160.	3.9	43
66	Correlation between Circulating Fungal Biomarkers and Clinical Outcome in Invasive Aspergillosis. <i>PLoS ONE</i> , 2015, 10, e0129022.	1.1	42
67	Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response. <i>Clinical Infectious Diseases</i> , 2017, 64, 1557-1563.	2.9	39
68	Invasive Aspergillosis After Kidney Transplant: Case-Control Study. <i>Clinical Infectious Diseases</i> , 2015, 60, 1505-1511.	2.9	38
69	Genetic deficiency of NOD2 confers resistance to invasive aspergillosis. <i>Nature Communications</i> , 2018, 9, 2636.	5.8	38
70	Treatment and timing in invasive mould disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, i37-i43.	1.3	37
71	Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2Â Gy TBI or ATG plus 8Â Gy TLI: a phase II randomized study from the Belgian Hematological Society. <i>Journal of Hematology and Oncology</i> , 2015, 8, 4.	6.9	37
72	IL-10 overexpression predisposes to invasive aspergillosis by suppressing antifungal immunity. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 867-870.e9.	1.5	37

#	ARTICLE	IF	CITATIONS
73	Fatal pulmonary infection in a leukaemic patient caused by <i>Hormographiella aspergillata</i> . <i>Journal of Medical Microbiology</i> , 2005, 54, 685-688.	0.7	36
74	Optimizing the diagnostic workflow for acute lymphoblastic leukemia by optical genome mapping. <i>American Journal of Hematology</i> , 2022, 97, 548-561.	2.0	36
75	Hedgehog pathway mutations in T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, e102-e105.	1.7	35
76	Fungal infections in solid organ transplantation: An update on diagnosis and treatment. <i>Transplantation Reviews</i> , 2019, 33, 77-86.	1.2	34
77	Serial Detection of Circulating Mucorales DNA in Invasive Mucormycosis: A Retrospective Multicenter Evaluation. <i>Journal of Fungi (Basel, Switzerland)</i> , 2019, 5, 113.	1.5	32
78	Beta- D -Glucan for Diagnosing <i>Pneumocystis</i> Pneumonia: a Direct Comparison between the Wako β -Glucan Assay and the Fungitell Assay. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	1.8	31
79	Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn). <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3315-3327.	1.3	30
80	Longitudinal, in vivo assessment of invasive pulmonary aspergillosis in mice by computed tomography and magnetic resonance imaging. <i>Laboratory Investigation</i> , 2016, 96, 692-704.	1.7	28
81	Defining Galactomannan Positivity in the Updated EORTC/MSGERC Consensus Definitions of Invasive Fungal Diseases. <i>Clinical Infectious Diseases</i> , 2021, 72, S89-S94.	2.9	28
82	Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients. <i>Clinical Therapeutics</i> , 2015, 37, 1317-1328.e2.	1.1	26
83	The microbiome-metabolome crosstalk in the pathogenesis of respiratory fungal diseases. <i>Virulence</i> , 2017, 8, 673-684.	1.8	25
84	The current management landscape: aspergillosis: Table 1. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, ii23-ii29.	1.3	24
85	Prospective Evaluation of the Turbidimetric β -D-Glucan Assay and 2 Lateral Flow Assays on Serum in Invasive Aspergillosis. <i>Clinical Infectious Diseases</i> , 2021, 72, 1577-1584.	2.9	24
86	Broad-Spectrum Antifungal Prophylaxis in Patients With Cancer at High Risk for Invasive Mold Infections: Counterpoint. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008, 6, 183-189.	2.3	23
87	A Multimodal Imaging Approach Enables <i>In Vivo</i> Assessment of Antifungal Treatment in a Mouse Model of Invasive Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	23
88	Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation. <i>Blood Advances</i> , 2020, 4, 4430-4437.	2.5	23
89	Burden of serious fungal infections in Belgium. <i>Mycoses</i> , 2015, 58, 1-5.	1.8	21
90	Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 953-963.	0.8	21

#	ARTICLE	IF	CITATIONS
91	Diagnosing Invasive Pulmonary Aspergillosis in Hematology Patients: a Retrospective Multicenter Evaluation of a Novel Lateral Flow Device. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	1.8	21
92	Point of care aspergillus testing in intensive care patients. <i>Critical Care</i> , 2020, 24, 642.	2.5	20
93	ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia. <i>Leukemia</i> , 2020, 34, 1907-1923.	3.3	20
94	New therapies for fungal pneumonia. <i>Current Opinion in Infectious Diseases</i> , 2009, 22, 183-190.	1.3	19
95	Accuracy and usability of the eGVHD app in assessing the severity of graft-versus-host disease at the 2017 EBMT annual congress. <i>Bone Marrow Transplantation</i> , 2018, 53, 490-494.	1.3	19
96	Lung microbiota predict invasive pulmonary aspergillosis and its outcome in immunocompromised patients. <i>Thorax</i> , 2022, 77, 283-291.	2.7	19
97	Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). <i>Leukemia</i> , 2022, 36, 1215-1226.	3.3	19
98	Serum amyloid P component is an essential element of resistance against <i>Aspergillus fumigatus</i> . <i>Nature Communications</i> , 2021, 12, 3739.	5.8	18
99	Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34); <i>DEK</i> shows a favourable outcome when performed in first complete remission. <i>British Journal of Haematology</i> , 2020, 189, 920-925.	1.2	16
100	Triazole-Resistance in Environmental <i>Aspergillus fumigatus</i> in Latin American and African Countries. <i>Journal of Fungi</i> (Basel, Switzerland), 2021, 7, 292.	1.5	16
101	Investigation of Saliva as an Alternative to Plasma Monitoring of Voriconazole. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1151-1160.	1.6	15
102	Plasmalyte: No Longer a Culprit in Causing False-Positive Galactomannan Test Results. <i>Journal of Clinical Microbiology</i> , 2016, 54, 795-797.	1.8	15
103	Use of chimerism analysis after allogeneic stem cell transplantation: Belgian guidelines and review of the current literature. <i>Acta Clinica Belgica</i> , 2021, 76, 500-508.	0.5	15
104	When to change treatment of acute invasive aspergillosis: an expert viewpoint. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 77, 16-23.	1.3	15
105	COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA). <i>Haematologica</i> , 2023, 108, 22-33.	1.7	15
106	A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients. <i>EClinicalMedicine</i> , 2021, 33, 100787.	3.2	14
107	<i>Pneumocystis jirovecii</i> pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipientsâ€™ response. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw580.	1.3	13
108	AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 683-691.	1.3	13

#	ARTICLE	IF	CITATIONS
109	Central nervous system disorders after hematopoietic stem cell transplantation: a prospective study of the Infectious Diseases Working Party of EBMT. <i>Journal of Neurology</i> , 2020, 267, 430-439.	1.8	13
110	Variable Correlation between Bronchoalveolar Lavage Fluid Fungal Load and Serum-(1,3)- β -D-Glucan in Patients with Pneumocystosis – A Multicenter ECMM Excellence Center Study. <i>Journal of Fungi (Basel)</i> , 2020, 6, 102.	0.6	10
111	Hmg1 Gene Mutation Prevalence in Triazole-Resistant <i>Aspergillus fumigatus</i> Clinical Isolates. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 227.	1.5	12
112	Posaconazole in prophylaxis and treatment of invasive fungal infections: a pharmacokinetic, pharmacodynamic and clinical evaluation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 539-550.	1.5	12
113	First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating Cyad-02, an Optimized Non Gene-Edited Engineered NKG2D CAR T-Cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. <i>Blood</i> , 2020, 136, 36-36.	0.6	12
114	Clinical considerations in the early treatment of invasive mould infections and disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, i29-i38.	1.3	11
115	A Mortality Prediction Rule for Hematology Patients with Invasive Aspergillosis Based on Serum Galactomannan Kinetics. <i>Journal of Clinical Medicine</i> , 2020, 9, 610.	1.0	10
116	Early diagnosis and preemptive therapy of pulmonary mold infections in high-risk patients. <i>Current Infectious Disease Reports</i> , 2008, 10, 459-465.	1.3	9
117	Pharmacokinetic drug evaluation of letermovir prophylaxis for cytomegalovirus in hematopoietic stem cell transplantation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 1197-1207.	1.5	9
118	Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole. <i>Mycoses</i> , 2018, 61, 868-876.	1.8	9
119	Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI. <i>Blood Advances</i> , 2019, 3, 1950-1960.	2.5	9
120	Proteome analysis of bronchoalveolar lavage fluids reveals host and fungal proteins highly expressed during invasive pulmonary aspergillosis in mice and humans. <i>Virulence</i> , 2020, 11, 1337-1351.	1.8	8
121	European confederation of medical mycology expert consultation – An ECMM excellence center initiative. <i>Mycoses</i> , 2020, 63, 566-572.	1.8	8
122	Posaconazole bioavailability of the solid oral tablet is reduced during severe intestinal mucositis. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1003-1009.	2.8	8
123	Diagnosing Invasive Mold Infections: What Is Next. <i>Current Fungal Infection Reports</i> , 2018, 12, 161-169.	0.9	7
124	Invasive pulmonary aspergillosis treatment duration in haematology patients in Europe: An EFISG, IDWP – EBMT, EORTC – IASG and SEIFEM survey. <i>Mycoses</i> , 2020, 63, 420-429.	1.8	7
125	Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. <i>Cancers</i> , 2021, 13, 672.	1.7	7
126	Prospective assessment of breakthrough infections and neurotoxicity and their association with cefepime trough concentrations in patients with febrile neutropenia. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106472.	1.1	7

#	ARTICLE	IF	CITATIONS
127	Gliotoxin and bis(methylthio)gliotoxin are not reliable as biomarkers of invasive aspergillosis. <i>Mycoses</i> , 2019, 62, 945-948.	1.8	6
128	Genetic Variation in PFKFB3 Impairs Antifungal Immunometabolic Responses and Predisposes to Invasive Pulmonary Aspergillosis. <i>MBio</i> , 2021, 12, e0036921.	1.8	6
129	Stable prevalence of triazole-resistance in <i>Aspergillus fumigatus</i> complex clinical isolates in a Belgian tertiary care center from 2016 to 2020. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 1774-1778.	0.8	6
130	Reply to Rijnders and Slobbe and to Donnelly and Leeflang. <i>Clinical Infectious Diseases</i> , 2010, 50, 1071-1073.	2.9	5
131	Toxoplasmosis after allogeneic haematopoietic cell transplantation: experience using a PCR-guided pre-emptive approach. <i>Clinical Microbiology and Infection</i> , 2022, 28, 440-445.	2.8	5
132	MAVS Expression in Alveolar Macrophages Is Essential for Host Resistance against <i>Aspergillus fumigatus</i> . <i>Journal of Immunology</i> , 2022, 209, 346-353.	0.4	5
133	A case with a cytogenetically cryptic variant of the inv(16)(p13q22)/t(16;16)(p13;q22). <i>Cancer Genetics</i> , 2014, 207, 231-232.	0.2	4
134	Defining standards of CARE for invasive fungal diseases in adult haematology patients: antifungal prophylaxis versus treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, ii21-ii26.	1.3	4
135	Pretreatment of Bronchoalveolar Lavage Fluid Samples with SLsolution Leads to False-Negative <i>Aspergillus Galactomannan</i> Levels. <i>Journal of Clinical Microbiology</i> , 2016, 54, 1171-1171.	1.8	3
136	Standards of CARE: what is considered "best practice" for the management of invasive fungal infections? A haematologist's and a mycologist's perspective. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, ii3-ii8.	1.3	3
137	<i>Invasive Fungal Infections.</i> , 2019, , 273-280.		3
138	Letermovir for prophylaxis of cytomegalovirus manifestations in adult allogeneic hematopoietic stem cell transplant recipients. <i>Future Microbiology</i> , 2019, 14, 175-184.	1.0	3
139	Retrospective chart review of hospitalizations and costs associated with the treatment of adults with Philadelphia-negative B-cell relapsed or refractory acute lymphoblastic leukemia in Belgium. <i>Acta Clinica Belgica</i> , 2017, 72, 429-433.	0.5	2
140	Diagnosis of Invasive Aspergillosis in Intensive Care Unit Patients. <i>Current Fungal Infection Reports</i> , 2020, 14, 166-173.	0.9	2
141	Reply to Mafaciolli and Pasqualotto. <i>Clinical Infectious Diseases</i> , 2020, 71, 2542-2543.	2.9	2
142	Multipotent Mesenchymal Stromal Cells for Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation: a Multicenter Prospective Study. <i>Blood</i> , 2019, 134, 37-37.	0.6	2
143	Ultra-performance liquid chromatography for quantification of amphotericin B plasma concentrations after use of liposomal amphotericin B. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 961-966.	1.3	2
144	An introduction to current standards of CARE in invasive fungal disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, ii2-ii2.	1.3	1

#	ARTICLE	IF	CITATIONS
145	Cefepime therapeutic drug monitoring: Evaluation of agreement between peripheral and central venous blood sampling. <i>Clinica Chimica Acta</i> , 2020, 510, 450-454.	0.5	1
146	A rare case of invasive pulmonary aspergillosis presenting as organizing pneumonia due to <i>Aspergillus niger</i> in an immunocompetent host. <i>Respiratory Medicine Case Reports</i> , 2021, 34, 101503.	0.2	1
147	Reply to Luppi et al. <i>Clinical Infectious Diseases</i> , 2020, 71, 3266-3266.	2.9	0
148	Voriconazole pharmacogenetics – Authors' reply. <i>Lancet</i> , The, 2021, 398, 578-579.	6.3	0
149	PAD Is a Highly Effective Regimen for the Treatment of Patients with Relapsed Refractory Multiple Myeloma.. <i>Blood</i> , 2006, 108, 5095-5095.	0.6	0
150	Echinocandins in the Treatment of Aspergillosis. , 0, , 435-443.		0
151	Addition of ATIR101, an Adjunctive Treatment Following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-Relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors. <i>Blood</i> , 2019, 134, 592-592.	0.6	0
152	Evolution of Clinically Relevant Subclones during Chemotherapy Treatment of ALL As Determined By Single-Cell DNA and RNA Sequencing. <i>Blood</i> , 2019, 134, 2749-2749.	0.6	0
153	Time-Restricted Versus Standard Duration Immunosuppression after Allogeneic Hematopoietic Stem Cell Transplantation: Results from the Prospective Randomized Phase III HOVON-96 Trial. <i>Blood</i> , 2019, 134, 371-371.	0.6	0
154	Post-Transplantation Cyclophosphamide for Gvhd Prophylaxis in Related and Unrelated Allogeneic Hematopoietic Cell Transplantation: Study from the SFGM-TC Registry. <i>Blood</i> , 2021, 138, 2883-2883.	0.6	0
155	Poor Outcome of Patients with COVID-19 after CAR T-Cell Therapy for B-Cell Malignancies: Results from a Multicenter Study on Behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. <i>Blood</i> , 2021, 138, 2818-2818.	0.6	0
156	Impact of Specific Adverse Cytogenetic Features on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome with Very Poor Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of EBMT. <i>Blood</i> , 2021, 138, 3953-3953.	0.6	0